As of June 30, 2026, TaiwanJ Pharmaceuticals Co., Ltd. carries a market capitalization of 574.47M, placing it among publicly traded companies globally. Its enterprise value stands at 516.37M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 574.47M |
| Enterprise Value | 516.37M |
As of June 30, 2026, TaiwanJ Pharmaceuticals Co., Ltd. has 80.12M shares outstanding.
| Shares Outstanding | 80.12M |
These figures are as of June 30, 2026.
| PB Ratio | 8.93 |
| P/TBV Ratio | 8.93 |
As of June 30, 2026, TaiwanJ Pharmaceuticals Co., Ltd. maintains a current ratio of 14.62, meaning it holds 14.6x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 14.62 |
| Quick Ratio | 13.39 |
| Debt / Equity | 3.22 |
These figures cover the twelve months ended June 30, 2026.
| Employee Count | 13.00 |
As of the close on November 17, 2026, TaiwanJ Pharmaceuticals Co., Ltd.'s stock has declined approximately 23.35% over the past 52 weeks. The 50-day moving average sits at 6.73, while the 200-day moving average is 7.39.
| 52-Week Price Change | -23.35% |
| 50-Day Moving Average | 6.73 |
| 200-Day Moving Average | 7.39 |
As of June 30, 2026, TaiwanJ Pharmaceuticals Co., Ltd. holds 60.17M in cash and equivalents against 2.07M in total debt, resulting in a net debt position of -60.17M. Total book value stands at 64.30M, with working capital of 61.20M providing operational flexibility.
| Cash & Cash Equivalents | 60.17M |
| Total Debt | 2.07M |
| Net Debt | -60.17M |
| Equity (Book Value) | 64.30M |
| Book Value Per Share | 0.80 |
| Working Capital | 61.20M |
TaiwanJ Pharmaceuticals Co., Ltd.'s most recent stock split took place on August 26, 2024 with a 853:857 split ratio.
| Last Split Date | 8/26/2024 |
| Split Ratio | 853:857 |
Already premium?